Revenue Breakdown
Composition ()
No data
Revenue Streams
Coherus Oncology Inc (CHRS) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is LOQTORZI, accounting for 96.5% of total sales, equivalent to $11.17M. Another important revenue stream is Other. Understanding this composition is critical for investors evaluating how CHRS navigates market cycles within the Pharmaceuticals industry.
Profitability & Margins
Evaluating the bottom line, Coherus Oncology Inc maintains a gross margin of 67.84%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -383.14%, while the net margin is -384.73%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively CHRS converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, CHRS competes directly with industry leaders such as CLLS and IKT. With a market capitalization of $246.63M, it holds a significant position in the sector. When comparing efficiency, CHRS's gross margin of 67.84% stands against CLLS's 32.13% and IKT's N/A. Such benchmarking helps identify whether Coherus Oncology Inc is trading at a premium or discount relative to its financial performance.
